MX2022012265A - Inhibicion dirigida utilizando oligonucleotidos ingenieria. - Google Patents
Inhibicion dirigida utilizando oligonucleotidos ingenieria.Info
- Publication number
- MX2022012265A MX2022012265A MX2022012265A MX2022012265A MX2022012265A MX 2022012265 A MX2022012265 A MX 2022012265A MX 2022012265 A MX2022012265 A MX 2022012265A MX 2022012265 A MX2022012265 A MX 2022012265A MX 2022012265 A MX2022012265 A MX 2022012265A
- Authority
- MX
- Mexico
- Prior art keywords
- engineered
- targeted inhibition
- engineered oligonucleotides
- oligonucleotides
- disclosed
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/316—Phosphonothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
Se divulgan en la presente oligonucleótidos genéticamente modificados para inhibición selectiva de la expresión y actividad del polipéptido. También se divulgan en la presente métodos para inhibir selectivamente la expresión y actividad del polipéptido poniendo en contacto un oligonucleótido genéticamente modificado con un polinucleótido que codifica el polipéptido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063004045P | 2020-04-02 | 2020-04-02 | |
PCT/US2021/025639 WO2021203043A2 (en) | 2020-04-02 | 2021-04-02 | Targeted inhibition using engineered oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022012265A true MX2022012265A (es) | 2023-01-11 |
Family
ID=77927597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022012265A MX2022012265A (es) | 2020-04-02 | 2021-04-02 | Inhibicion dirigida utilizando oligonucleotidos ingenieria. |
Country Status (12)
Country | Link |
---|---|
US (4) | US20230132602A1 (es) |
EP (1) | EP4127175A2 (es) |
JP (1) | JP2023521042A (es) |
KR (1) | KR20230023612A (es) |
CN (1) | CN116096890A (es) |
AU (1) | AU2021246530A1 (es) |
BR (1) | BR112022019889A2 (es) |
CA (1) | CA3174286A1 (es) |
CO (1) | CO2022015141A2 (es) |
IL (1) | IL296957A (es) |
MX (1) | MX2022012265A (es) |
WO (1) | WO2021203043A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240032998A (ko) | 2021-07-14 | 2024-03-12 | 마이레큘, 인크. | 신경근육장애를 위한 올리고뉴클레오티드 및 이의 조성물 |
WO2023122347A2 (en) | 2021-12-23 | 2023-06-29 | Mirecule, Inc. | Compositions for delivery of polynucleotides |
KR20230102595A (ko) * | 2021-12-30 | 2023-07-07 | 주식회사 이노제닉스 | 포스파티딜이노시톨 3-키나아제 촉매 소단위 알파 유전자의 3'비번역 부위에 특이적으로 결합하는 핵산 절편 및 그 응용 |
CN117402251B (zh) * | 2023-12-15 | 2024-02-23 | 中国医学科学院基础医学研究所 | 一种抗小g蛋白rbj的抗体及其应用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US4401796A (en) | 1981-04-30 | 1983-08-30 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
ES2465574T3 (es) | 2002-05-03 | 2014-06-06 | Duke University | Un método para regular la expresión génica |
US8106180B2 (en) * | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性rnaが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
EP1838870A2 (en) | 2004-12-29 | 2007-10-03 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF MICRORNAS AND THEIR TARGET MRNAs |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US20090209621A1 (en) | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
ITMI20051248A1 (it) | 2005-07-01 | 2007-01-02 | Vimar Spa | Modem per bus per impianti elettrici civili ed industriali |
CN101296702B (zh) | 2005-09-12 | 2012-11-28 | 俄亥俄州立大学研究基金会 | 用于诊断或治疗bcl2相关癌症的组合物和方法 |
US8603991B2 (en) | 2005-11-18 | 2013-12-10 | Gradalis, Inc. | Individualized cancer therapy |
ES2387250T3 (es) | 2005-12-12 | 2012-09-19 | The University Of North Carolina At Chapel Hill | Microarn que regulan la proliferación y diferenciación de células musculares |
ES2557411T3 (es) | 2006-01-05 | 2016-01-25 | The Ohio State University Research Foundation | Métodos y composiciones basados en microARN para el diagnóstico y el tratamiento de cánceres sólidos |
WO2007143752A2 (en) | 2006-06-09 | 2007-12-13 | The Regents Of The University Of California | Targets in breast cancer for prognosis or therapy |
WO2007149521A2 (en) | 2006-06-20 | 2007-12-27 | The Johns Hopkins University | Nucleotide motifs providing localization elements and methods of use |
WO2008069940A2 (en) | 2006-12-06 | 2008-06-12 | Albert Einstein College Of Medicine Of Yeshiva University | Multi-microrna methods and compositions |
WO2008088858A2 (en) | 2007-01-17 | 2008-07-24 | The Johns Hopkins University | Compositions and methods featuring micronas for treating neoplasia |
WO2009012263A2 (en) * | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
JP5654347B2 (ja) | 2007-07-31 | 2015-01-14 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | ミオシンの発現及び筋線維の同一性を制御するマイクロrna |
WO2009075817A1 (en) | 2007-12-06 | 2009-06-18 | Minerva Biotechnologies Corporation | Method for treating cancer using interference rna |
JP2010094122A (ja) | 2008-06-12 | 2010-04-30 | Keio Gijuku | バイオマーカーとしてのマイクロrnaを用いた頭頸部腫瘍の診断・治療選択 |
US8729041B2 (en) | 2008-12-03 | 2014-05-20 | The Johns Hopkins University | Compositions and methods for treating hepatic neoplasia |
CN102803284B (zh) | 2009-06-08 | 2015-11-25 | 米拉根医疗公司 | 用于miRNA抑制剂和模拟物的化学修饰基序 |
WO2011034811A1 (en) | 2009-09-17 | 2011-03-24 | Sigma-Aldrich Co. | Short rna mimetics |
US20120302626A1 (en) * | 2009-12-04 | 2012-11-29 | Sandeep Dave | Microrna and use thereof in identification of b cell malignancies |
US8768630B2 (en) * | 2010-02-19 | 2014-07-01 | The Regents Of The University Of Michigan | miRNA target prediction |
AU2011252799B2 (en) | 2010-05-14 | 2015-05-14 | Cold Spring Harbor Laboratory | Compositions and methods for treating leukemia |
DK2426203T3 (en) | 2010-09-02 | 2016-11-07 | Université de Mons | Agents that are useful in the treatment of muscular dystrophy, facioscapulohumeral |
MY165507A (en) | 2011-02-03 | 2018-03-28 | Mirna Therapeutics Inc | Synthetic mimics of mir-34 |
CN103459598B (zh) | 2011-02-03 | 2016-08-10 | 米尔纳医疗股份有限公司 | Mir-124的合成模拟物 |
WO2013016352A1 (en) | 2011-07-25 | 2013-01-31 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
CA2843636A1 (en) | 2011-07-29 | 2013-02-07 | Fred Hutchinson Cancer Research Center | Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
US9428749B2 (en) | 2011-10-06 | 2016-08-30 | The Board Of Regents, The University Of Texas System | Control of whole body energy homeostasis by microRNA regulation |
TWI516267B (zh) | 2011-11-07 | 2016-01-11 | 臺北榮民總醫院 | 抑制癌症或腫瘤細胞之類癌幹細胞特性及抗化學及放射治療特性的醫藥組合物 |
WO2013120038A2 (en) | 2012-02-10 | 2013-08-15 | Regents Of The University Of Minnesota | Morpholino targeting dux4 for treating fshd |
US11293064B2 (en) * | 2013-05-02 | 2022-04-05 | Thomas Jefferson University | Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases |
US9518300B2 (en) | 2014-04-14 | 2016-12-13 | Dana-Farber Cancer Institute, Inc. | Composition and method for treating a hematological malignancy |
JP6514717B2 (ja) | 2014-04-25 | 2019-05-15 | ザ チルドレンズ メディカル センター コーポレーション | 異常ヘモグロビン症を治療するための組成物および方法 |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
US20180305689A1 (en) | 2015-04-22 | 2018-10-25 | Mina Therapeutics Limited | Sarna compositions and methods of use |
WO2017007886A2 (en) | 2015-07-08 | 2017-01-12 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting dux4 gene expression and uses thereof |
CN117757794A (zh) * | 2016-03-07 | 2024-03-26 | 美国政府(由卫生和人类服务部的部长所代表) | 微小rna及其使用方法 |
US11518995B2 (en) | 2017-09-19 | 2022-12-06 | Children's National Medical Center | Gapmers and methods of using the same for the treatment of muscular dystrophy |
EP3668997A4 (en) * | 2017-10-02 | 2021-05-19 | Research Institute at Nationwide Children's Hospital | MIARN SCREENING SYSTEM FOR FABRIC SPECIFIC INTERFERENCE |
US10676744B2 (en) * | 2017-10-13 | 2020-06-09 | University Of South Carolina | Modulation of adipose tissue macrophage phenotype by use of MicroRNA-30 |
US11268305B2 (en) | 2018-05-17 | 2022-03-08 | Kiekert Ag | Latching system for a motor vehicle |
MX2021001284A (es) | 2018-08-02 | 2021-07-15 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y sus usos para el tratamiento de distrofia muscular facioescapulohumeral. |
CN113710283A (zh) | 2019-03-29 | 2021-11-26 | 田边三菱制药株式会社 | 用于调节dux4的表达的化合物、方法和医药组合物 |
TW202117015A (zh) | 2019-07-12 | 2021-05-01 | 日商第一三共股份有限公司 | 使DUX4 pre-mRNA之剪接變化之反義寡核苷酸 |
BR112022013603A2 (pt) | 2020-01-10 | 2022-09-13 | Dyne Therapeutics Inc | Complexos de direcionamento a músculo e usos dos mesmos para tratar distrofia muscular facioescapuloumeral |
TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
BR112022020945A2 (pt) | 2020-04-17 | 2022-12-27 | Nevada Res & Innovation Corporation | Inibição por crispr para distrofia muscular fácioescápulo- umeral |
GB202009618D0 (en) | 2020-06-24 | 2020-08-05 | Ucl Business Ltd | Therapeutics for the treatment of FSHD |
US20230287108A1 (en) | 2020-07-23 | 2023-09-14 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
CA3186746A1 (en) | 2020-07-23 | 2022-01-27 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
WO2022043566A1 (en) | 2020-08-31 | 2022-03-03 | Merck Patent Gmbh | Method and device for manufacturing of solid oral dosage forms |
WO2022051332A1 (en) | 2020-09-01 | 2022-03-10 | Ultragenyx Pharmaceutical Inc. | Dux4 inhibitors and methods of use thereof |
MX2023002853A (es) | 2020-09-11 | 2023-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresion de dux4, composiciones de dichos agentes, y metodos de uso. |
CA3189071A1 (en) | 2020-09-11 | 2022-03-17 | Xiaokai Li | Skeletal muscle delivery platforms and methods of use |
JP2022055361A (ja) | 2020-09-28 | 2022-04-07 | 田辺三菱製薬株式会社 | Dux4の発現を調節するための医薬組成物 |
-
2021
- 2021-04-02 IL IL296957A patent/IL296957A/en unknown
- 2021-04-02 KR KR1020227038205A patent/KR20230023612A/ko unknown
- 2021-04-02 CN CN202180040335.4A patent/CN116096890A/zh active Pending
- 2021-04-02 WO PCT/US2021/025639 patent/WO2021203043A2/en active Application Filing
- 2021-04-02 AU AU2021246530A patent/AU2021246530A1/en active Pending
- 2021-04-02 CA CA3174286A patent/CA3174286A1/en active Pending
- 2021-04-02 BR BR112022019889A patent/BR112022019889A2/pt unknown
- 2021-04-02 EP EP21780542.3A patent/EP4127175A2/en active Pending
- 2021-04-02 JP JP2022560272A patent/JP2023521042A/ja active Pending
- 2021-04-02 MX MX2022012265A patent/MX2022012265A/es unknown
- 2021-04-02 US US17/915,215 patent/US20230132602A1/en active Pending
-
2022
- 2022-03-11 US US17/692,644 patent/US11597930B2/en active Active
- 2022-03-11 US US17/692,630 patent/US11795459B2/en active Active
- 2022-10-24 CO CONC2022/0015141A patent/CO2022015141A2/es unknown
-
2023
- 2023-01-17 US US18/155,163 patent/US20230295626A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220213481A1 (en) | 2022-07-07 |
US20220213480A1 (en) | 2022-07-07 |
BR112022019889A2 (pt) | 2023-03-07 |
EP4127175A2 (en) | 2023-02-08 |
IL296957A (en) | 2022-12-01 |
CO2022015141A2 (es) | 2022-12-30 |
AU2021246530A1 (en) | 2022-11-03 |
US20230132602A1 (en) | 2023-05-04 |
CN116096890A (zh) | 2023-05-09 |
WO2021203043A3 (en) | 2021-11-11 |
US20230295626A1 (en) | 2023-09-21 |
KR20230023612A (ko) | 2023-02-17 |
US11795459B2 (en) | 2023-10-24 |
WO2021203043A2 (en) | 2021-10-07 |
US11597930B2 (en) | 2023-03-07 |
JP2023521042A (ja) | 2023-05-23 |
CA3174286A1 (en) | 2021-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022012265A (es) | Inhibicion dirigida utilizando oligonucleotidos ingenieria. | |
NZ733882A (en) | Compositions for modulating c9orf72 expression | |
MX2021012126A (es) | Composiciones y métodos para inhibir la expresión génica en el sistema nervioso central. | |
MX2019002004A (es) | Metodos para editar la metilacion del adn. | |
MX2018011243A (es) | Metodos para promover la salud de las plantas usando enzimas libres y microorganismos que sobreexpresan enzimas. | |
MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
EP2032686A4 (en) | DEVICES AND SYSTEMS FOR THE CREATION OF ORDINATED DNA AMASES | |
MX2018008266A (es) | Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer. | |
MY151551A (en) | Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors | |
JO2872B1 (en) | New vehicles | |
BR112021024463A2 (pt) | Oligonucleotídeos e métodos de uso para o tratamento de doenças neurológicas | |
MX2015015564A (es) | Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos. | |
MX2021014206A (es) | Oligonucleotidos gapmer modificados y metodos de uso. | |
MX2017009427A (es) | Inhibidores de mir-92 y usos de los mismos. | |
GB201202561D0 (en) | Treatment of skin disorders | |
MX2020006297A (es) | Variantes de cd19. | |
JOP20200044A1 (ar) | مثبط انتقائي egfr طافر exon 18 و/أو exon 21 | |
PH12021550736A1 (en) | Double-stranded ribonucleic acid inhibiting expression of complement c5 | |
MX2019007947A (es) | Hoja de acero para estampacion en caliente. | |
SA517390005B1 (ar) | حفاز لهدرجة هيدروكربونات أروماتية، وطريقة معالجة بالهدرجة واستخداماتها فيها | |
SG11202111575WA (en) | Engineered microorganisms and methods for improved aldehyde dehydrogenase activity | |
MX2018001126A (es) | Oligonucleotidos terapeuticos. | |
MX2017001927A (es) | Plantas de tomate que permiten el establecimiento de los acaros. | |
GB202305377D0 (en) | Systems and methods for targeted neuromodulation | |
MX2017014855A (es) | Oligonucleotidos atisentido para tratar epidermolisis bullosa distrofica. |